Allstate Corp Purchases New Stake in Humana Inc. (NYSE:HUM)

Allstate Corp bought a new stake in shares of Humana Inc. (NYSE:HUM) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 3,567 shares of the insurance provider’s stock, valued at approximately $905,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HUM. Orion Portfolio Solutions LLC boosted its stake in shares of Humana by 3.7% during the 4th quarter. Orion Portfolio Solutions LLC now owns 4,834 shares of the insurance provider’s stock valued at $1,226,000 after buying an additional 171 shares during the period. denkapparat Operations GmbH purchased a new stake in shares of Humana during the fourth quarter worth $323,000. Pictet Asset Management Holding SA boosted its position in Humana by 18.8% during the fourth quarter. Pictet Asset Management Holding SA now owns 72,803 shares of the insurance provider’s stock valued at $18,471,000 after purchasing an additional 11,523 shares during the last quarter. High Ground Investment Management LLP grew its stake in Humana by 43.5% in the fourth quarter. High Ground Investment Management LLP now owns 424,403 shares of the insurance provider’s stock valued at $107,675,000 after purchasing an additional 128,636 shares in the last quarter. Finally, New Age Alpha Advisors LLC acquired a new position in Humana in the 4th quarter worth about $2,960,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of HUM stock opened at $264.35 on Tuesday. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a market capitalization of $31.91 billion, a P/E ratio of 26.57, a P/E/G ratio of 2.05 and a beta of 0.57. The stock has a 50 day moving average of $269.77 and a two-hundred day moving average of $273.07. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, equities analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.34%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on HUM shares. Truist Financial boosted their price target on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Piper Sandler increased their price target on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. StockNews.com downgraded shares of Humana from a “buy” rating to a “hold” rating in a report on Tuesday, March 18th. Barclays upped their price objective on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. cut their target price on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Eighteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.